# OnCo record nct07431281 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07431281/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07431281", "NCT07431281" ;
  schema:name "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2"@en ;
  schema:alternateName "CLARITY-Gastric 02"@en ;
  schema:description "A phase 3 trial of Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, Oxaliplatin and Zolbetuximab in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07431281/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07431281> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-02-03" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/>, <https://onco.cc/cancers/gastric-cldn18-2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cmg901/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/zolbetuximab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .